Judith Karp

Medicine & Life Sciences

1. Acute Myeloid Leukemia 100%
2. Leukemia 57%
3. Cytarabine 40%
4. tipifarnib 23%
5. alvocidib 22%
6. Bone Marrow 22%
7. Farnesyltranstransferase 16%
8. Drug Therapy 16%
9. Neoplasms 16%
10. Therapeutics 15%
11. Hematologic Neoplasms 13%
12. Mitoxantrone 12%
13. Precursor Cell Lymphoblastic Leukemia-Lymphoma 11%
14. veliparib 10%
15. Pharmaceutical Preparations 9%
16. Survival 9%
17. Apoptosis 9%
18. Agranulocytosis 8%
19. In Vitro Techniques 8%
20. Infections 8%
21. Daunorubicin 7%
22. Pharmacokinetics 7%
23. Histone Deacetylase Inhibitors 7%
24. Growth 6%
25. Poly(ADP-ribose) Polymerase Inhibitors 6%
26. Amphotericin B 6%
27. Cytogenetics 6%
28. Topotecan 6%
29. Cyclophosphamide 6%
30. Myelodysplastic Syndromes 6%
31. Clinical Trials 6%
32. Mutation 6%
33. Transferases 5%
34. Etoposide 5%
35. entinostat 5%
36. Clofarabine 5%
37. Recurrence 5%
38. Norfloxacin 5%
39. Disease-Free Survival 5%
40. Lymphocytes 5%
41. 3-aminopyridine-2-carboxaldehyde thiosemicarbazone 5%